MedTrace Logo

Surgery and BCG in Treating Patients With Bladder Cancer

NCT00002990 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1288

Last updated 2013-06-12

No results posted yet for this study

Summary

RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing.

PURPOSE: This randomized phase III trial is studying four different regimens of BCG and comparing how well they work in treating patients who have undergone surgery for bladder cancer.

Conditions

Interventions

BIOLOGICAL

BCG vaccine

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • A. P.M. Van Der Meijden, MD, PhD · Jeroen Bosch Ziekenhuis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-03-31
Primary Completion
2005-04-30

Countries

  • Austria
  • Belgium
  • France
  • Greece
  • Israel
  • Italy
  • Netherlands
  • Portugal
  • Romania
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002990 on ClinicalTrials.gov